Literature DB >> 15185229

Preferential proliferation of attenuated Salmonella typhimurium within neuroblastoma.

Leland J Soto1, Brent S Sorenson, Brent W Nelson, Scott J Solis, Arnold S Leonard, Daniel A Saltzman.   

Abstract

BACKGROUND/
PURPOSE: Attenuated Salmonella typhimurium, a facultative intracellular parasite that colonizes the liver, has been shown to accumulate within extrahepatic malignancies. The authors sought to define a mechanism for attenuated Salmonella accumulation within cancer cells compared with hepatocytes.
METHODS: Invasion and intracellular proliferation of attenuated Salmonella was assessed through an in vitro assay performed on neuroblasoma, osteosarcoma, hepatoma, and colon adenocarcinoma cell lines and compared with freshly isolated mouse hepatocytes.
RESULTS: The efficiency of attenuated S typhimurium invasion into hepatocytes was greater than any malignant cell line (3.8 v 0.46; P <.04). However, the intracellular proliferation of the bacteria was most abundant within neuroblastoma, exceeding the proliferation within hepatocytes (14.3 v 6.2; P <.01).
CONCLUSIONS: Attenuated S typhimurium may prove to be an effective in vivo immunotherapy for the local delivery of therapeutic proteins to neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15185229     DOI: 10.1016/j.jpedsurg.2004.02.042

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  4 in total

1.  Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model.

Authors:  Brent Sorenson; Kaysie Banton; Lance Augustin; Sean Barnett; Karen McCulloch; Joshua Dorn; Natalie Frykman; Arnold Leonard; Daniel Saltzman
Journal:  Biologics       Date:  2010-03-24

2.  Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma.

Authors:  Brent S Sorenson; Kaysie L Banton; Natalie L Frykman; Arnold S Leonard; Daniel A Saltzman
Journal:  Clin Orthop Relat Res       Date:  2008-04-18       Impact factor: 4.176

3.  A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma.

Authors:  Sara E Fritz; Michael S Henson; Emily Greengard; Amber L Winter; Kathleen M Stuebner; Una Yoon; Vicki L Wilk; Antonella Borgatti; Lance B Augustin; Jaime F Modiano; Daniel A Saltzman
Journal:  Vet Med Sci       Date:  2016-06-06

4.  A Phase I, Dose Escalation, Single Dose Trial of Oral Attenuated Salmonella typhimurium Containing Human IL-2 in Patients With Metastatic Gastrointestinal Cancers.

Authors:  Thomas J Gniadek; Lance Augustin; Janet Schottel; Arnold Leonard; Daniel Saltzman; Edward Greeno; Gerald Batist
Journal:  J Immunother       Date:  2020-09       Impact factor: 4.912

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.